219 related articles for article (PubMed ID: 25587960)
21. Clinical and cost effectiveness of bevacizumab + FOLFIRI combination versus FOLFIRI alone as first-line treatment of metastatic colorectal cancer in South Korea.
Lee EK; Revil C; Ngoh CA; Lister J; Kwon JM; Park MH; Park SJ; Park YS; Shin SJ; Lee MA; Lee NS; Zang DY; Bae EJ; Kang MJ
Clin Ther; 2012 Jun; 34(6):1408-19. PubMed ID: 22657254
[TBL] [Abstract][Full Text] [Related]
22. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A
Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
[TBL] [Abstract][Full Text] [Related]
23. Oral anti-angiogenesis treatment plus chemotherapy is not more efficacious than bevacizumab plus chemotherapy in metastatic colorectal cancer.
Oncology (Williston Park); 2011 Nov; 25(12):1232. PubMed ID: 22229221
[No Abstract] [Full Text] [Related]
24. Two steps forward in the treatment of colorectal cancer.
Mayer RJ
N Engl J Med; 2004 Jun; 350(23):2406-8. PubMed ID: 15175443
[No Abstract] [Full Text] [Related]
25. [Advances in the treatment of metastatic colorectal cancer with bevacizumab].
Longo F; Mansueto G
Tumori; 2006; 92(5):suppl 1-12. PubMed ID: 17168449
[No Abstract] [Full Text] [Related]
26. The price tag on progress--chemotherapy for colorectal cancer.
Schrag D
N Engl J Med; 2004 Jul; 351(4):317-9. PubMed ID: 15269308
[No Abstract] [Full Text] [Related]
27. Late anastomotic dehiscence during bevacizumab therapy for patients with colorectal cancer.
Garant A; Des Groseilliers S; Martin L; Ferland É; Vuong T
Clin Oncol (R Coll Radiol); 2011 Sep; 23(7):497-8. PubMed ID: 21576010
[No Abstract] [Full Text] [Related]
28. Bevacizumab in colorectal cancer.
Sonpavde G
N Engl J Med; 2004 Oct; 351(16):1690-1; author reply 1690-1. PubMed ID: 15483292
[No Abstract] [Full Text] [Related]
29. Comment on 'Treatment of colorectal cancer with and without bevacizumab: a phase III study'.
Boisen MK; Johansen JS; Larsen O; Jensen BV
Oncology; 2011; 80(1-2):138-9. PubMed ID: 21677460
[No Abstract] [Full Text] [Related]
30. Efficacy of S-1 in colorectal cancer.
Miyamoto Y; Sakamoto Y; Yoshida N; Baba H
Expert Opin Pharmacother; 2014 Aug; 15(12):1761-70. PubMed ID: 25032886
[TBL] [Abstract][Full Text] [Related]
31. Chemotherapy and immunotherapy in metastatic colorectal cancer.
Pohlmann PR; Mernaugh RL; Goff LW
N Engl J Med; 2009 May; 360(20):2134; author reply 2135-6. PubMed ID: 19439750
[No Abstract] [Full Text] [Related]
32. [Clinical research of bevacizumab in combination with irinotecan, fluorouracil and leucovorin for advanced metastatic colorectal cancer].
Cui F; Chen JZ; Wan C; Chen B; Luo RC; Zheng H
Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Jul; 12(4):374-7. PubMed ID: 19598023
[TBL] [Abstract][Full Text] [Related]
33. FOLFIRI with cetuximab or bevacizumab: FIRE-3.
Price TJ; Townsend AR; Peeters M
Lancet Oncol; 2014 Dec; 15(13):e582-e583. PubMed ID: 25456374
[No Abstract] [Full Text] [Related]
34. FOLFIRI with cetuximab or bevacizumab: FIRE-3.
Pietrantonio F; Iacovelli R; Di Bartolomeo M; de Braud F
Lancet Oncol; 2014 Dec; 15(13):e581. PubMed ID: 25456372
[No Abstract] [Full Text] [Related]
35. [Application of monoclonal antibody in combination with irinotecan in the treatment of colorectal cancer].
Li J
Zhonghua Zhong Liu Za Zhi; 2006 Oct; 28(10):796-7. PubMed ID: 17366800
[No Abstract] [Full Text] [Related]
36. Response to chemotherapy in metastatic colorectal cancer after exposure to oxaliplatin in the adjuvant setting.
Moreau LC; Rajan R; Thirlwell MP; Alcindor T
Anticancer Res; 2013 Apr; 33(4):1765-8. PubMed ID: 23564831
[TBL] [Abstract][Full Text] [Related]
37. FOLFIRI with cetuximab or bevacizumab: FIRE-3.
Petrelli F; Coinu A; Barni S
Lancet Oncol; 2014 Dec; 15(13):e581-e582. PubMed ID: 25456373
[No Abstract] [Full Text] [Related]
38. Chemotherapy and immunotherapy in metastatic colorectal cancer.
Frati L; Codacci-Pisanelli G
N Engl J Med; 2009 May; 360(20):2134-5; author reply 2135-6. PubMed ID: 19445031
[No Abstract] [Full Text] [Related]
39. Always look at the bright side of drugs?
Nygren P
Acta Oncol; 2015 Feb; 54(2):145-7. PubMed ID: 25608927
[No Abstract] [Full Text] [Related]
40. Sudden death related to toxicity in a patient on capecitabine and irinotecan plus bevacizumab intake: pharmacogenetic implications.
Dahan L; Ciccolini J; Evrard A; Mbatchi L; Tibbitts J; Ries P; Norguet E; Mercier C; Iliadis A; Ouafik L; Lacarelle B; Seitz JF
J Clin Oncol; 2012 Feb; 30(4):e41-4. PubMed ID: 22184401
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
